Archive - Boutique Biotech

August 2024

NewAmsterdam Pharma in the spotlight

Obicetrapib Shows Promising Results in Phase 3 BROOKLYN Trial

Aug 19 •

Bohdan (Bo) Khomtchouk, Ph.D.

March 2024

January 2024

December 2023

Happy holidays from Boutique Biotech!

Bio M&A recap for 2023 and trends we're watching for 2024

Dec 26, 2023 •

Bohdan (Bo) Khomtchouk, Ph.D.

Structure Therapeutics and POINT Biopharma in the spotlight

Updates and future outlook on $GPCR and $PNT, including $LNTH in the context of Novartis and Lilly

Dec 19, 2023 •

Bohdan (Bo) Khomtchouk, Ph.D.

Mural Oncology in the spotlight

Deep dive on $MURA financials and market timing

Dec 14, 2023 •

Bohdan (Bo) Khomtchouk, Ph.D.

Diabetes medical devices in the spotlight

Recent updates on $PODD, $TNDM, $MODD, et al.

Dec 8, 2023 •

Bohdan (Bo) Khomtchouk, Ph.D.

Pfizer in the spotlight (part II)

Pfizer's obesity drug fails; market shifts to other GLP-1s.

Dec 4, 2023 •

Bohdan (Bo) Khomtchouk, Ph.D.

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts